Description
First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial carcinoma (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim results of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial
Read the full article here:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02095-7/fulltext?dgcid=youtube_video_lancet_tl_esmo_short
* * *
Continue this conversation on social! Follow us today at…
https://bsky.app/profile/thelancet.com
https://Facebook.com/TheLancetMedicalJournal
https://Instagram.com/TheLancetGroup
https://LinkedIn.com/company/The-Lancet